Načítá se...
A lower dosage of imatinib in patients with gastrointestinal stromal tumors with toxicity of the treatment
This study investigated the efficiency and safety of imatinib in the lower dose (300 mg/d) in patients with gastrointestinal stromal tumor (GIST) who cannot tolerate imatinib in the standard dose (400 mg/d). Steady-state imatinib trough concentration (Cmin) values in 18 patients with GIST who were t...
Uloženo v:
| Vydáno v: | Medicine (Baltimore) |
|---|---|
| Hlavní autoři: | , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Wolters Kluwer Health
2016
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5266004/ https://ncbi.nlm.nih.gov/pubmed/27930532 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000005488 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|